Currax Pharmaceuticals LLC

Reporting payments is a legal requirement; large totals often reflect large product portfolios.

$1.4Mgeneral payments (2019-2025)
$70Kresearch payments (2019-2025)
19,693clinicians paid

General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.

General payments by year

2019 $20K
2020 $144K
2021 $303K
2022 $180K
2023 $244K
2024 $232K
2025 $269K

General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.

Products most associated with its payments

Specialties it works with most

Internal Medicine $287K
Family Medicine $265K
Family $162K
Neurology (Psychiatry & Neurology) $93K
Physician Assistant $63K
Gastroenterology (Internal Medicine) $61K

Clinicians with the largest reported totals

Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.

ClinicianLocationSpecialtyGeneral payments (2019-2025)
Andres Acosta Rochester, MN Gastroenterology (Internal Medicine) $58,129.47
Angela Fitch Boston, MA Obesity Medicine (Internal Medicine) $51,191.56
Ethan Lazarus Denver, CO Family Medicine $35,098.23
Anthony Auriemma Westmont, IL Family Medicine $29,898.32
Angela Golden Munds Park, AZ Family $28,678.11
Scott Kahan Chevy Chase, MD Public Health & General Preventive Medicine $27,194.36
Fatima Stanford Boston, MA Internal Medicine $24,978.53
Milton Pressler Carmel, IN Cardiovascular Disease $24,560.00
Craig Primack Scottsdale, AZ Pediatrics $24,554.33
Robert Kushner Chicago, IL Internal Medicine $21,639.23

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.